Valneva

Valneva Scotland Limited is the UK manufacturing and R&D subsidiary of Valneva SE, a specialty vaccine company.

Operating from an MHRA-authorised GMP facility in Livingston, the site produces commercial and pipeline vaccines including IXCHIQ, the world's first approved chikungunya vaccine, and IXIARO for Japanese encephalitis.

The pipeline includes a Phase 3 Lyme disease vaccine candidate developed in partnership with Pfizer, and further candidates targeting Shigella and Zika.